Haemorrhagic stroke – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Haemorrhagic stroke – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Lyophilized Plasma Compared to Standard Fluid Solutions for Patients with Hemorrhagic Shock in the Emergency Room https://clinicaltrials.eu/trial/study-of-lyophilized-plasma-compared-to-standard-fluid-solutions-for-patients-with-hemorrhagic-shock-in-the-emergency-room/ Wed, 29 Apr 2026 15:08:13 +0000 https://clinicaltrials.eu/trial/study-of-lyophilized-plasma-compared-to-standard-fluid-solutions-for-patients-with-hemorrhagic-shock-in-the-emergency-room/ This study is looking at patients who have hemorrhagic shock, which is a serious condition that happens when a person loses a large amount of blood. When someone is in hemorrhagic shock, their blood pressure drops very low and their body cannot get enough oxygen to the organs, which can be life-threatening. The study will test two different types of fluids that doctors give to these patients through a vein. One treatment is called LyoPlas N-W, which is a special form of human plasma that has been freeze-dried and can be prepared very quickly for use. The other treatment is ELO-MEL isoton, which is a standard fluid solution containing salts and minerals such as sodium chloride, potassium chloride, magnesium chloride hexahydrate, calcium chloride dihydrate, and sodium acetate trihydrate that doctors commonly use to replace lost fluids.

The purpose of this study is to find out whether giving freeze-dried plasma early in the emergency room works better than giving the standard salt solution to patients in hemorrhagic shock. The researchers believe that the freeze-dried plasma might help patients recover faster because it can be prepared and given much more quickly than regular plasma, it may help protect the blood vessels, and it stays in the bloodstream longer. They will measure how quickly patients improve by checking the level of a substance called lactate in the blood, which goes up when the body is not getting enough oxygen. The study will also look at whether using freeze-dried plasma means that patients need less of the salt solution, which could help avoid problems that sometimes happen when too much fluid is given.

During the study, patients who come to the emergency room with hemorrhagic shock will receive either the freeze-dried plasma or the standard salt solution through an infusion into their vein. The doctors will monitor how the patients respond to the treatment and will measure various signs of recovery. The study will compare the two treatments to see which one helps patients stabilize more quickly and which one leads to better outcomes overall.

]]> Study on Eptacog Alfa for Treating Acute Hemorrhagic Stroke in Patients with Brain Bleeding https://clinicaltrials.eu/trial/study-on-eptacog-alfa-for-treating-acute-hemorrhagic-stroke-in-patients-with-brain-bleeding/ Wed, 29 Apr 2026 14:59:06 +0000 https://clinicaltrials.eu/trial/study-on-eptacog-alfa-for-treating-acute-hemorrhagic-stroke-in-patients-with-brain-bleeding/ This clinical trial is focused on studying a condition known as acute hemorrhagic stroke, which occurs when there is sudden bleeding in the brain. The treatment being tested is called recombinant coagulation Factor VIIa, also known by its code name rFVIIa. This treatment is a type of protein that helps the blood to clot, potentially reducing the effects of the bleeding. The trial will compare the effects of rFVIIa with a placebo to see if it can improve recovery after a stroke caused by bleeding in the brain.

The purpose of the study is to determine if administering rFVIIa within two hours of the stroke can lead to better outcomes for patients. Participants in the study will receive either the rFVIIa treatment or a placebo. The study will monitor the participants’ recovery over a period of time, using a scale that measures how well they can perform daily activities. This scale is known as the modified Rankin Scale (mRS), which is commonly used to assess the level of disability or dependence after a stroke.

The trial aims to find the best time window and group of patients who might benefit the most from this treatment. The study will track the participants’ progress for up to 180 days to see if there are improvements in their condition. The results will help determine if rFVIIa can be an effective treatment for those who experience a stroke due to bleeding in the brain.

]]> Study on the Safety and Effects of Ixodes ricinus Contact Phase Inhibitor in Adults with Spontaneous Brain Bleeding https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ixodes-ricinus-contact-phase-inhibitor-in-adults-with-spontaneous-brain-bleeding/ Wed, 29 Apr 2026 14:24:53 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ixodes-ricinus-contact-phase-inhibitor-in-adults-with-spontaneous-brain-bleeding/ This clinical trial is focused on studying a condition known as spontaneous intracerebral hemorrhage, which is a type of bleeding that occurs inside the brain without any obvious cause. The study is testing a new treatment called Ixodes ricinus Contact Phase Inhibitor, also known by its code name Ir-CPI. This treatment is given as a solution through an infusion into the veins. The main goal of the study is to evaluate how safe and tolerable this new treatment is for patients who have experienced this type of brain bleed.

Participants in the study will receive either the new treatment or a placebo. The study will monitor various health indicators to ensure the safety of the participants, such as checking for any adverse events, conducting physical and neurological examinations, and performing blood tests to assess biochemistry and coagulation. The study will also use CT scans to measure changes in the volume of the hemorrhage and other related factors.

The study is designed to provide important information about the potential benefits and risks of using Ir-CPI in treating spontaneous intracerebral hemorrhage. By participating in this study, researchers hope to gather data that could lead to new treatment options for this serious condition. The study is expected to continue for several years to ensure comprehensive results are obtained.

]]>